Considerable variation seen in magnitude of antibody response, from 5 to 7,882 AU\/mL, following two doses of mRNA COVID-19 vaccine<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, July 2, 2021 (HealthDay News) — Patients with multiple myeloma (MM) mount a highly variable antibody response after receipt of a two-dose mRNA COVID-19 vaccination regimen, according to a study published online June 28 in Cancer Cell<\/em>.<\/p>\n Oliver Van Oekelen, from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues analyzed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-binding immunoglobulin (Ig)G antibody levels in 320 MM patients who received COVID-19 vaccinations (69.1 percent BNT162b2; 27.2 percent mRNA-1273; 3.8 percent unknown) in early 2021.<\/p>\n Two hundred sixty of the participants had SARS-CoV-2 spike-binding IgG antibody levels measured at least 10 days after receipt of the second vaccine dose. The researchers found that 84.2 percent of the 260 participants mounted measurable SARS-CoV-2 spike-binding IgG antibody levels, with considerable variation in magnitude (median, 149 AU\/mL; range, 5 to 7,882 AU\/mL); 15.8 percent had values below the level of detection. In a control group of 67 matched health care workers, vaccine-induced antibody responses were more homogenous (median, 300 AU\/mL; range, 21 to 3,335 AU\/mL); none had antibody levels below the level of detection. There were 10 cases of COVID-19 in MM patients after mRNA vaccination (seven after one dose; three after both doses). Six patients received outpatient treatment and four required subsequent hospitalization.<\/p>\n “Our findings underscore the need for routine serological monitoring of MM patients following COVID-19 vaccination to allow for personalized risk reduction measures in the context of relaxing mask and social distancing mandates for vaccinated individuals,” the authors write. <\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry; the Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and Newcastle disease virus-based SARS-CoV-2 vaccines, listing one coauthor as inventor.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n